BioCentury
ARTICLE | Finance

Venture Report: Tubulis’ big B round to advance ADCs, Relation adds to seed financing

Plus new rounds for Mission, Asgard and more

March 14, 2024 10:52 PM UTC

With investor interest in ADCs remaining high,  Tubulis GmbH announces plans to take its first two ADC candidates into the clinic with the raise of an additional €128 million ($138.8 million) in a series B2 round co-led by EQT Life Sciences and Nexttech Invest. The funding will support proof-of-concept studies for TUB-040, which targets SLC34A2 in ovarian cancer, and TUB-030, an ADC targeting 5T4 for solid tumors. 

The biotech said the first Phase I/IIa trial would start this year. In parallel, the Germany-based company plans to build out its suite of ADC technologies to include new payloads, and expand its footprint with a U.S. subsidiary. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article